Earnings Call Insights: Kiniksa Pharmaceuticals International, plc (KNSA) Q4 2025 Sanj Patel, CEO, stated that "ARCALYST revenue continues to grow, driven by the expanding adoption of IL-1 alpha and ...

Kiniksa transitions from survival risk to growth, targeting dominance in the pericarditis market with robust cash flow and expanding margins. KNSA's Arcalyst drives revenue growth, with 2026 guidance ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Kiniksa Pharmaceuticals (KNSA) is outperforming this year. The stock has advanced slightly more than 40% since my previous update where I outlined how I liked the big pipeline changes and the ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported strong second-quarter 2026 financial results, raised its full-year ARCALYST sales guidance, and advanced its cardiovascular pipeline with the Phase 3 ...

Kiniksa Pharmaceuticals is set to begin a Phase 2/3 clinical trial for its drug KPL-387, aimed at treating recurrent pericarditis, in mid-2025. The company has noted that data from the ongoing Phase 1 ...

Kiniksa Pharmaceuticals reports Q1 2025 net revenue of $137.8 million for ARCALYST, forecasts 2025 revenue of $590-$605 million. Kiniksa Pharmaceuticals reported significant financial growth in Q1 ...

LONDON, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company developing and commercializing novel therapies for diseases ...